0.35Open0.35Pre Close0 Volume20 Open Interest44.00Strike Price0.00Turnover118.02%IV22.62%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type0.1288Delta0.0361Gamma103.34Leverage Ratio-0.0886Theta0.0008Rho13.31Eff Leverage0.0104Vega
Exelixis Stock Discussion
Breakthrough: CABOMETYX Becomes First FDA-Approved Treatment for All Advanced NET Cancers
Exelixis Reveals Breakthrough Cancer Pipeline: 4 Novel Drugs Show Promise in Early Data
2.Based on the fourth-quarter and fiscal year 2024 financial report, Exelixis, Inc. demonstrated excellent performance. For the fourth quarter, the company reported net income of $139.9 millio...
Revolutionary Kidney Cancer Treatment Doubles Patient Survival: Final 5-Year Trial Results Revealed
No comment yet